Lates News

date
16/06/2025
The journalist learned that Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer division, has decided to resign and seek external development opportunities. His last working day will be June 30th. AstraZeneca confirmed the news to the journalist. Public information shows that Lai Minglong joined AstraZeneca in June 2017 as Vice President of AstraZeneca's China Cardiovascular and Metabolic Business, and was promoted to General Manager of AstraZeneca China in 2018. (Southern Finance).
Latest
See all latestmore